Author Correction: Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial

• Maria Vittoria Dieci,
• Giancarlo Bisagni,
• Stefania Bartolini,
• Antonio Frassoldati,
• Roberto Vicini,
• Sara Balduzzi,
• Roberto D’amico,
• Pierfranco Conte,
• Valentina Guarneri

Affiliations

Maria Vittoria Dieci

Department of Surgery, Oncology and Gastroenterology, University of Padova

Giancarlo Bisagni

Department of Oncology and Advanced Technologies, Oncology Unit, Azienda USL-IRCCS

Stefania Bartolini

Nervous System Medical Oncology Department, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto delle Scienze Neurologiche di Bologna

Antonio Frassoldati

Clinical Oncology, Department of Translational Medicine and for Romagna, S. Anna University Hospital

Roberto Vicini

Department of Medical and Surgical Sciences for Children & Adults, University of Modena

Sara Balduzzi

Department of Medical and Surgical Sciences for Children & Adults, University of Modena

Roberto D’amico

Department of Medical and Surgical Sciences for Children & Adults, University of Modena

Pierfranco Conte

Veneto Oncology Network

Valentina Guarneri

Department of Surgery, Oncology and Gastroenterology, University of Padova